Sort

Search

01/06/2025 ACR/EULAR 2022 CLASSIFICATION CRITERIA COMPARED TO THE ACR 1990 CLASSIFICATION CRITERIA IN THE ARTESER REGISTRY OF GIANT CELL ARTERITIS
De Miguel, E, Dominguez-Alvaro, M, Hernández-Rodríguez, I, Silva-Díaz, M, Otano, JMB, Moya, P, Cabañas, MT, Angeles, VAN, Calvet, J, Casafont-Solé, I, Ivorra, JAR, Labrada-Arrabal, S, Vasques-Rocha, M, Iñiguez, CL, Dorta, AG, Fernández, CC, Villar, MA, Mas, AJ, Prado, FJ, Blanco, R. ACR/EULAR 2022 CLASSIFICATION CRITERIA COMPARED TO THE ACR 1990 CLASSIFICATION CRITERIA IN THE ARTESER REGISTRY OF GIANT CELL ARTERITIS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B849. PMID:. IF:20.600(Q1/1D).
01/06/2025 VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort
García-Escudero, P, López-Gómez, M, López, BM, Dorta, AG, Frade-Sosa, B, Lizarzaburu, MS, Rúa-Figueroa, I, Fiallo, DV, de Miera, FJTS, Melero-Gonzalez, RB, Santos, DD, Miranda, JA, Belando, CG, Boselli, G, Boteanu, AL, Villalobos, L, Selaya, CC, Santos, CS, Alvarez, ED, Font, J, Alonso, ER, Araguás, ET, Merayo, EE, Rodriguez-Laguna, M, Monjo, I, Gómez, IV, Vela-Casasempere, P, Merino, C, Martínez, MI, Beriain, JAH, Ruiz-Román, A, Calvo-Alén, J. VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort. RHEUMATOLOGY. 2025; 64(6)DOI:10.1093/rheumatology/keaf094. PMID:39937690. IF:4.400(Q1/1D).
01/06/2025 INITIAL THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE
Bjorkekjar, HJ, Bruni, C, Broch, K, Brunborg, C, Delgado, PC, Airo, P, Simeon-Aznar, CP, Truchetet, ME, Giollo, A, Balbir-Gurman, A, Martin, M, Denton, C, Gabrielli, A, Del Galdo, F, Vonk, M, Fretheim, H, Bitter, H, Midtvedt, O, Andreassen, A, Hoie, S, Tanaka, Y, Riemekasten, G, Mueller-Ladner, U, Matucci-Cerinic, M, Castellvi, I, Siegert, E, Hachulla, E, Molberg, O, Distler, O, Hoffmann-Vold, AM. INITIAL THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1890. PMID:. IF:20.600(Q1/1D).
01/06/2025 TRANSITION IN BONE METABOLISM: INSIGHTS FROM A NATIONAL SURVEY IN SPAIN
Lopez, BPM, Lopez-Corbeto, M, Zavala, RG, Torrent, RB, Gonzalez-Fernandez, MI, Perello, CM, Sevilla-Perez, B, Fontana, NP, Pascual, AR, Ildefonso, MMS, Regueira, SM, Alcaniz, P, Gonzalez, JCN, Grana, J. TRANSITION IN BONE METABOLISM: INSIGHTS FROM A NATIONAL SURVEY IN SPAIN. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1745. PMID:. IF:20.600(Q1/1D).
01/06/2025 COMPARISON OF BARICITINIB AND TOFACITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: INSIGHTS FROM A REAL-WORLD COHORT USING PROPENSITY SCORE ADJUSTMENTS
Lasanta, MAL, Saborit, MC, Panos, HB, Lizarzaburu, MS, Ruiz-Esquide, V, Vilaseca, DR, Nack, A, Perez-Garcia, C, Bernarde, J, Guillen, AG, Aguilar, JR, Cuervo, A, Valls, M, Gomez, CG, Minguez, S, Novell, RM, Alarcon, PE, Martinez-Morillo, M, Grau, CP, Busquets-Perez, N, Park, HS, Gomez-Puerta, JA, Perez, SH, Palau, NM, Sanmarti, R, Mateo-Soria, L, Diaz-Torne, C, Coromina, H, Alarcon, GS. COMPARISON OF BARICITINIB AND TOFACITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: INSIGHTS FROM A REAL-WORLD COHORT USING PROPENSITY SCORE ADJUSTMENTS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B2477. PMID:. IF:20.600(Q1/1D).
01/06/2025 AMBISPECTIVE, MULTICENTER REGISTRY OF TREATMENT WITH ANIFROLUMAB IN REAL LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM SPANISH RHEUMATOLOGY DEPARTMENTS (ANIFRO-REU): EFFICACY AND SAFETY AT 3-AND 6-MONTH FOLLOW-UP VISITS
Salman-Monte, TC, Carrion-Barberá, I, Triginer, L, Riveros-Frutos, A, Font, J, Garcia-Villanueva, MJ, Garrote-Corral, S, Galindo, M, Polo, CD, González, IA, Bernabéu, P, Casasempere, PV, Morales, CM, Alvarez, ED, Cortés-Hernández, J, Moreno, SS, Giráldez, CR, Gil, JJF, Hernández, A, Magallares, BP, Garcia, MMP, Cid, CMF, Hernández, S, Ros, I, García-Aparicio, A, Sala-Icardo, L, Gómez-Puerta, JA, Frade-Sosa, B, Garcia-Cirera, S, Bufort, MG, Martínez-Barrio, J, de Salazar, JRG, del Amo, ND, Fito-Manteca, C, Torrente-Segarra, V, Heredia, S, Brandy-Garcia, A, Lucea, ER, Zarrabeitia, LR, Urruticoechea-Arana, A, Pego-Reigosa, JM, Rúa-Figueroa, IJ. AMBISPECTIVE, MULTICENTER REGISTRY OF TREATMENT WITH ANIFROLUMAB IN REAL LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM SPANISH RHEUMATOLOGY DEPARTMENTS (ANIFRO-REU): EFFICACY AND SAFETY AT 3-AND 6-MONTH FOLLOW-UP VISITS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1338. PMID:. IF:20.600(Q1/1D).
01/06/2025 A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis
Bjorkekjaer, HJ, Bruni, C, Broch, K, Brunborg, C, Carreira, PE, Airò, P, Simeón-Aznar, CP, Truchetet, ME, Giollo, A, Balbir-Gurman, A, Martin, M, Denton, CP, Gabrielli, A, Del Galdo, F, Vonk, MC, Fretheim, H, Bitter, H, Midtvedt,O, Andreassen, A, Hoie, S, Tanaka, Y, Riemekasten, G, Mueller-Ladner, U, Matucci-Cerinic, M, Castellví, I, Siegert, E, Hachulla, E, Molberg,O, Distler, O, Hoffmann-Vold, AM, EUSTAR Collaborators. A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis. RHEUMATOLOGY. 2025; 64(6)DOI:10.1093/rheumatology/keaf053. PMID:39878955. IF:4.400(Q1/1D).
01/06/2025 Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.
Ochsenreither, S, Anguera, G, Dieter, S, Trikalinos, N, Fu, SQ, Fernández, BC, Ferrandiz, AC, Kim, SY, Rodriguez, LM, Berg, KCG, Hassan, HIB, Rosholm, A, Fredriksen, AB. Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(16_SUPPL)DOI:10.1200/JCO.2025.43.16_suppl.2639. PMID:. IF:41.900(Q1/1D).
01/06/2025 Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer
Herbst, RS, John, T, Grohé, C, Goldman, JW, Kato, T, Laktionov, K, Bonanno, L, Tiseo, M, Majem, M, Dómine, M, Ahn, MJ, Kowalski, DM, Pérol, M, Sriuranpong, V, Özgüroglu, M, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Robichaux, J, Hartmaier, R, Tsuboi, M, Wu, YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. NATURE MEDICINE. 2025; 31(6)DOI:10.1038/s41591-025-03577-y. PMID:40097663. IF:50.000(Q1/1D).
01/06/2025 Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study
Tibau, A, Cliff, ERS, Romano, A, Borrell, M, Molto, C, Kesselheim, AS. Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study. Eclinicalmedicine. 2025; 84DOI:10.1016/j.eclinm.2025.103088. PMID:40687736. IF:10.000(Q1/1D).
01/06/2025 Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia
Jiménez-Vicente, C, Arribas, I, Pomares, H, Ramil, G, Castaño-Diez, S, Pérez-Valencia, AI, Sturla, AL, López-Guerra, M, Martinez-Roca, A, Zugasti, I, Guijarro, F, Cortés-Bullich, A, Merchán, B, Triguero, A, Monge, I, Tuca, A, Oñate, G, Garrido, A, Sierra, J, Arnan, M, Esteve, J, Díaz-Beyá, M. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. HAEMATOLOGICA. 2025; 110(6)DOI:10.3324/haematol.2024.286589. PMID:39844754. IF:10.100(Q1/2D).
01/06/2025 Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers
Barroeta, I, Videla, L, Carmona-Iragui, M, Fortea, J, Rafii, MS. Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70258. PMID:40528298. IF:11.100(Q1/1D).
01/06/2025 Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome
Sauer, M, Gomes, BF, Shahrouki, P, Lantero-Rodriguez, J, Montoliu-Gaya, L, Camporesi, E, Belbin, O, Alcolea, D, Kumar, A, Sharma, M, Singh, S, Brinkmalm, G, Gobom, J, Carmona-Iragui, M, Schöll, M, Janelidze, S, Deep, G, Blennow, K, Zetterberg, H, Brinkmalm, A, Lleó, A, Fortea, J, Hansson, O, Ashton, NJ, Nilsson, J. Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70241. PMID:40522075. IF:11.100(Q1/1D).
01/06/2025 Bridging perspectives: The value of collaboration between Traditional Healing Practitioners and Medical Doctors in dementia research and care in South Africa
McGlinchey, E, Ranchod, K, Stroebel, R, Lusizi, B, Galvin, M, Kleinhans, AV, Fortea, J, Hoffman, J, Makanya, S. Bridging perspectives: The value of collaboration between Traditional Healing Practitioners and Medical Doctors in dementia research and care in South Africa. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70370. PMID:40566835. IF:11.100(Q1/1D).
01/06/2025 Adverse drug events associated with emergency departments visits
Ramos, JR, Perrín, RS, Martín, MAG, Clemente, YC, Díez, MA, Pinto, AD, Díaz, AS, Almela, AFD, Serrano, PS, Grande, ASL, Blanco, CC. Adverse drug events associated with emergency departments visits. EMERGENCIAS. 2025; 37(3)DOI:10.55633/s3me/025.2025. PMID:. IF:6.300(Q1/1D).
01/06/2025 Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview
Delaby, C, Ladang, A, Martinez-Yriarte, J, Zecca, C, Logroscino, G, Koertvelyessy, P, Tumani, H, Parchi, P, Quadrio, I, Hart, M, Olsen, DA, Alcolea, D, Blennow, K, Fortea, J, Lleo, A, Algeciras-Schimnich, A, Ayrignac, X, Bedel, A, Santos, GAA, Borelli, W, Bouaziz-Amar, E, Baldeiras, I, Bigot-Corbel, E, Bjerke, M, Perez, MC, Casoli, T, Chabrashvili, T, Chapman, MD, Cusato, J, Dursun, E, Fourier, A, Galimberti, D, Gezen-Ak, D, Gordon, BA, Gouju, J, Florez, SD, Sanchez, JH, Herwerth, M, Imperiale, D, Kaczorowski, F, Kasuga, K, Keshavan, A, Khalil, M, Kuhle, J, Leithner, C, Lewczuk, P, Letournel, F, Tsolaki, M, Giuffre, GM, Blanc, MC, Mroczko, B, Rodriguez, JEM, Musso, G, Kulczynska-Przybik, A, Nogueira, L, Paquet, C, Baiardi, S, Gaetani, L, Parnetti, L, Garay, RP, Poesen, K, Quillard-Muraine, M, Borja, ER, Schraen, S, Terracciano, D, Bachhuber, F, Halbgebauer, S, Tzartos, S, Tzartos, J, Unterwalder, N, Vermunt, L, Wellington, CL, Zetterberg, H, Teunissen, C, Lehmann, S. Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70343. PMID:40551293. IF:11.100(Q1/1D).
01/06/2025 Clinical-epidemiological aspects, hospitalization, and reconsultations in older patients with atrial fibrillation in emergency departments in Spain (EDEN-35 study): sex-disaggregated analysis
Coll-Vinent, B, Hernández, NM, Marco, NC, Boixeda, C, Rodríguez, JJ, Alquézar-Arbé, A, Alonso, CF, Burillo-Putze, G, Montero-Pérez, FJ, del Castillo, JG, Miró, O. Clinical-epidemiological aspects, hospitalization, and reconsultations in older patients with atrial fibrillation in emergency departments in Spain (EDEN-35 study): sex-disaggregated analysis. EMERGENCIAS. 2025; 37(3)DOI:10.55633/s3me/035.2025. PMID:40531120. IF:6.300(Q1/1D).
01/06/2025 Discrepancies in assessing intellectual disability levels in adults with Down syndrome: Implications for dementia diagnosis
Soriano, LD, Sandkühler, K, Videla, L, Benejam, B, Carmona-Iragui, M, Wlasich, E, Kustermann, J, Barroeta, I, Vaqué-Alcázar, L, Rodríguez-Baz, I, Bejanin, A, Fernández, S, Arranz, J, Arriola-Infante, JE, Maure-Blesa, L, Juan, AS, Nübling, G, Wagemann, O, Stockbauer, A, Hassenstab, J, Levin, J, Fortea, J. Discrepancies in assessing intellectual disability levels in adults with Down syndrome: Implications for dementia diagnosis. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70307. PMID:40528393. IF:11.100(Q1/1D).
01/06/2025 Down syndrome in Africa: Challenges, opportunities, and future directions
McGlinchey, E, Tewolde, S, He, AMD, Fortea, J, Mbakile-Mahlanza, L, Tefera, A, Epenge, E, Hassenstab, J, Jaeck, A, Ranchod, K, El-Jaafary, S, Levin, J, Salama, M, Rubenstein, E, Akinyemi, R, Akinyemi, T, Farombi, T, Lawlor, B, Ikanga, J, Ashton, NJ, Stout, S, Balls-Berry, J, Kleinhans, AV, Maina, R, Merali, Z. Down syndrome in Africa: Challenges, opportunities, and future directions. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70388. PMID:40538002. IF:11.100(Q1/1D).
01/06/2025 The history of Down syndrome-associated Alzheimer's disease; past, present, and future
Maure-Blesa, L, Carmona-Iragui, M, Lott, I, Head, E, Wisniewski, T, Rafii, MS, Espinosa, J, Flórez, J, Mobley, WC, Holland, A, Strydom, A, Zaman, S, Fortea, J. The history of Down syndrome-associated Alzheimer's disease; past, present, and future. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70158. PMID:40469048. IF:11.100(Q1/1D).